ALK and non-small cell lung carcinoma: Crizotinib, initially designed as a MET inhibitor in 2007, was first approved in 2011 by the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic ALK-rearrangement NSCLC.